Resistencia a la insulina y su impacto en la enfermedad renal crónica asociada a obesidad
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | |
| dc.contributor.author | Rico Fontalvo, Jorge | |
| dc.contributor.author | Rodríguez Yánez, Tomas | |
| dc.contributor.author | Montejo Hernández, Juan | |
| dc.contributor.author | Jiménez Quintero, Javier | |
| dc.contributor.author | Daza Arnedo, Rodrigo | |
| dc.date.accessioned | 2025-11-06T14:33:35Z | |
| dc.date.available | 2025-11-06T14:33:35Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | La obesidad es un problema de salud pública a nivel mundial. Hace parte del llamado síndrome metabólico (SM) y se correlaciona con un elevado riesgo de resultados adversos cardiovasculares. La obesidad se correlaciona con la aparición y progresión de la enfermedad renal crónica (ERC) y se han descrito mecanismos directos e indirectos que afectan los riñones en pacientes obesos. La enfermedad renal crónica relacionada con la obesidad (ERC-Ob) es un trastorno multifacético que afecta a pacientes con ERC en diversos grados. Dentro de los mecanismos inflamatorios, hemodinámicos y metabólicos se destaca la resistencia a la insulina y la hiperinsulinemia compensatoria que contribuyen a la hiperfiltración glomerular, albuminuria, incremento de la permeabilidad vascular, disfunción endotelial, estrés oxidativo y mayor producción citoquinas proinflamatorias que aceleran el deterioro de la función renal. Por ello nos proponemos revisar el impacto y los efectos de la resistencia a la insulina como mecanismo de iniciación y desarrollo de la ERC-Ob. | spa |
| dc.description.abstract | Obesity is a global public health problem. It is part of the so-called metabolic syndrome (MS) and is correlated with an elevated risk of adverse cardiovascular outcomes. Obesity is correlated with the onset and progression of chronic kidney disease (CKD) and direct and indirect mechanisms affecting the kidneys in obese patients have been described. Obesity-related chronic kidney disease (CKD-Ob) is a multifaceted disorder that affects patients with CKD to varying degrees. These inflammatory, hemodynamic, and metabolic mechanisms include insulin resistance and compensatory hyperinsulinemia, contributing to glomerular hyperfiltration, albuminuria, increased vascular permeability, endothelial dysfunction, oxidative stress, and increased production of proinflammatory cytokines that accelerate the decline of kidney function. Therefore, we propose to review the impact and effects of insulin resistance as a mechanism of initiation and development of CKD-Ob. | eng |
| dc.format.mimetype | ||
| dc.identifier.citation | Rico Fontalvo J, Rodríguez Yánez T, Montejo Hernández J, Jiménez Quintero J, Daza Arnedo R. Resistencia a la insulina y su impacto en la enfermedad renal crónica asociada a obesidad. Rev. Soc. Parag. Nefrol. [Internet]. 31 de octubre de 2025 [citado 6 de noviembre de 2025];3(2):80-8. Disponible en: https://revista.spn.org.py/index.php/rspn/article/view/56 | |
| dc.identifier.doi | https://doi.org/10.70108/nefrologiapy.2025.3.2.80 | |
| dc.identifier.issn | 3006-2217 (Electrónico) | |
| dc.identifier.issn | 3006-2209 (Impreso) | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/17086 | |
| dc.identifier.url | https://revista.spn.org.py/index.php/rspn/article/view/56 | |
| dc.language.iso | spa | |
| dc.publisher | Sociedad Paraguaya de Nefrología | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.source | Revista de la Sociedad Paraguaya de Nefrología | spa |
| dc.source | Vol. 3 No. 2 Año 2025 | spa |
| dc.subject | Obesidad | spa |
| dc.subject | Resistencia a la insulina | spa |
| dc.subject | Inflamación | spa |
| dc.subject | Enfermedad renal crónica | spa |
| dc.subject.keywords | Obesity | eng |
| dc.subject.keywords | Insulin resistance | eng |
| dc.subject.keywords | Inflammation | eng |
| dc.subject.keywords | Chronic kidney disease | eng |
| dc.title | Resistencia a la insulina y su impacto en la enfermedad renal crónica asociada a obesidad | spa |
| dc.type.driver | info:eu-repo/semantics/article | |
| dc.type.spa | Artículo científico | |
| dcterms.references | Nawaz S, Chinnadurai R, Al‐Chalabi S, Evans P, Kalra PA, Syed AA, et al. Obesity and chronic kidney disease: A current review. Obes Sci Pract. 2022 July 19;9(2):61–74. | eng |
| dcterms.references | Whaley-Connell A, Sowers JR. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. Kidney Int. 2017Aug; 92(2):313–23. | eng |
| dcterms.references | Wang X, Lin R, Ji X, Xu Z, Chang H, Gu X, et al. Insulin resistance mediates the association between adiposity markers and incident chronic kidney disease: Findings from the UK Biobank prospective cohort study. Diabetes Res Clin Pract. 2025 July;225:112255. | eng |
| dcterms.references | Rico-Fontalvo J, Daza-Arnedo R, Rodríguez-Yanez T, Osorio W, Suarez-Romero B, Soto O, et al. Obesidad y enfermedad renal crónica. Una mirada desde los mecanismos fisiopatológicos.: Revisión narrativa. Rev Soc Ecuat Nefrol Diálisis Traspl. 2022 Sept 30;10(2):97–107. | spa |
| dcterms.references | Rico-Fontalvo J, Daza-Arnedo R, Montejo-Hernandez J, Cardona-Blanco M, Rodríguez-Yanez T. Reflexiones de la enfermedad renal crónica asociada a obesidad: de una vieja relación causal hasta un enfoque basado en la fenotipificación. Rev Soc Ecuat Nefrol Diálisis Traspl. 2022 Sept 30;10(2):137–9. | spa |
| dcterms.references | Lu JL, Kalantar-Zadeh K, Ma JZ, Quarles LD, Kovesdy CP. Association of body mass index with outcomes in patients with CKD. J Am Soc Nephrol JASN. 2014 Sept;25(9):2088–96. | eng |
| dcterms.references | Bello AK, Alrukhaimi M, Ashuntantang GE, Basnet S, Rotter RC, Douthat WG, et al. Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. Kidney Int Suppl. 2017 Oct;7(2):122–9. | eng |
| dcterms.references | Schrauben SJ, Jepson C, Hsu JY, Wilson FP, Zhang X, Lash JP, et al. Insulin resistance and chronic kidney disease progression, cardiovascular events, and death: findings from the chronic renal insufficiency cohort study. BMC Nephrol. 2019 Feb 20;20(1):60. | eng |
| dcterms.references | Whaley-Connell A, Sowers JR. Insulin Resistance in Kidney Disease: Is There a Distinct Role Separate from That of Diabetes or Obesity? Cardiorenal Med. 2017 Dec;8(1):41–9. | eng |
| dcterms.references | Soltani Z, Washco V, Morse S, Reisin E. The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches. Curr Hypertens Rep. 2015 Feb;17(2):7. | eng |
| dcterms.references | Cases A, Broseta JJ, Marqués M, Cigarrán S, Julián JC, Alcázar R, et al. La definición del síndrome cardiovascular- reno-metabólico (cardiovascular-kidney-metabolic syndrome) y su papel en la prevención, estatificación del riesgo y tratamiento. Una oportunidad para la Nefrología. Nefrología. 2024 Nov 1;44(6):771–83. | eng |
| dcterms.references | León-Román J, López-Martínez M, Esteves A, Ciudin A, Núñez-Delgado S, Álvarez T, et al. Obesity-Related Kidney Disease: A Growing Threat to Renal Health. Int J Mol Sci. 2025 Jan;26(14):6641. | eng |
| dcterms.references | Duan M, Zhao X, Li S, Miao G, Bai L, Zhang Q, et al. Metabolic score for insulin resistance (METS-IR) predicts all-cause and cardiovascular mortality in the general population: evidence from NHANES 2001–2018. Cardiovasc Diabetol. 2024 July 10;23(1):243. | eng |
| dcterms.references | Hojs R, Ekart R, Bevc S, Vodošek Hojs N. Chronic Kidney Disease and Obesity. Nephron. 2023;147(11):660–4. | eng |
| dcterms.references | Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon- Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 May 25;143(21):e984–1010. | eng |
| dcterms.references | Hill MA, Yang Y, Zhang L, Sun Z, Jia G, Parrish AR, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021 June;119:154766. | eng |
| dcterms.references | Badmus OO, Hillhouse SA, Anderson CD, Hinds TD, Stec DE. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. Clin Sci Lond Engl 1979. 2022 Sept 30;136(18):1347–66. | eng |
| dcterms.references | Zbrzeźniak-Suszczewicz J, Winiarska A, Perkowska- Ptasińska A, Stompór T. Obesity-Related Glomerulosclerosis— How Adiposity Damages the Kidneys. Int J Mol Sci. 2025 June 28;26(13):6247. | eng |
| dcterms.references | Rico-Fontalvo J, Ciudin A, Correa-Rotter R, Díaz-Crespo FJ, Bonanno C, Lecube A, et al. SEN, SLANH, and SEEDO Consensus report on Obesity related kidney disease. Proposal for a new classification. Kidney Int. 2025 July 3;S0085-2538(25)00505-8. | eng |
| dcterms.references | Hall JE. The kidney, hypertension, and obesity. Hypertens Dallas Tex 1979. 2003 Mar;41(3 Pt 2):625–33. | eng |
| dcterms.references | Friedman AN, Kaplan LM, le Roux CW, Schauer PR. Management of Obesity in Adults with CKD. J Am Soc Nephrol JASN. 2021 Feb 18;ASN.2020101472. | eng |
| dcterms.references | Flier JS, Kahn CR. Insulin: A pacesetter for the shape of modern biomedical science and the Nobel Prize. Mol Metab. 2021 Oct;52:101194. | eng |
| dcterms.references | Daza-Arnedo R, Rico-Fontalvo J, Aroca-Martínez G, Rodríguez-Yanez T, Martínez-Ávila MC, Almanza-Hurtado A, et al. Insulin and the kidneys: a contemporary view on the molecular basis. Front Nephrol. 2023;3:1133352. | eng |
| dcterms.references | Rico-Fontalvo J, Aroca G, Cabrales J, Daza-Arnedo R, Yánez-Rodríguez T, Martínez-Ávila MC, et al. Molecular Mechanisms of Diabetic Kidney Disease. Int J Mol Sci. 2022 Aug 4;23(15):8668. | eng |
| dcterms.references | Rahman MS, Hossain KS, Das S, Kundu S, Adegoke EO, Rahman MA, et al. Role of Insulin in Health and Disease: An Update. Int J Mol Sci. 2021 June 15;22(12):6403. | eng |
| dcterms.references | Lay A, Coward RJ. Recent advances in our understanding of insulin signalling to the podocyte. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2014 June;29(6):1127–33. | eng |
| dcterms.references | Li L, Garikepati RM, Tsukerman S, Kohan D, Wade JB, Tiwari S, et al. Reduced ENaC activity and blood pressure in mice with genetic knockout of the insulin receptor in the renal collecting duct. Am J Physiol - Ren Physiol. 2013 Feb 1;304(3):F279–88. | eng |
| dcterms.references | Fontalvo JER, Arnedo RD, Raad M, Pájaro N, Guerrero JC, Oviedo AV, et al. Agonistas del receptor Glp-1: Desde su efecto fisiológico en el sistema incretina hasta du rol en enfermedad renal diabetica. Arch Med. 2021;17(2):2. | spa |
| dcterms.references | Singh S, Sharma R, Kumari M, Tiwari S. Insulin receptors in the kidneys in health and disease. World J Nephrol. 2019 Jan 21;8(1):11–22. | eng |
| dcterms.references | Horita S, Nakamura M, Suzuki M, Satoh N, Suzuki A, Seki G. Selective Insulin Resistance in the Kidney. BioMed Res Int. 2016;2016:5825170. | eng |
| dcterms.references | Akalın N, Köroğlu M, Harmankaya Ö, Akay H, Kumbasar B. Comparison of insulin resistance in the various stages of chronic kidney disease and inflammation. Ren Fail. 2015 Mar;37(2):237–40. | eng |
| dcterms.references | Fahmy AM, El Shall N, Kabbash I, El Ahwal L, Selim A. Lipid accumulation product and visceral adiposity index: two indices to predict metabolic syndrome and insulin resistance in chronic kidney disease patients. Endocr Regul. 2023 Jan 1;57(1):99–105. | eng |
| dcterms.references | Piwkowska A, Rogacka D, Kasztan M, Angielski S, Jankowski M. Insulin increases glomerular filtration barrier permeability through dimerization of protein kinase G type Iα subunits. Biochim Biophys Acta. 2013 June;1832(6):791–804. | eng |
| dcterms.references | Coward R, Fornoni A. Insulin signaling: implications for podocyte biology in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2015 Jan;24(1):104–10. | eng |
| dcterms.references | Welsh GI, Hale LJ, Eremina V, Jeansson M, Maezawa Y, Lennon R, et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab. 2010 Oct 6;12(4):329–40. | eng |
| dcterms.references | Wasik AA, Lehtonen S. Glucose Transporters in Diabetic Kidney Disease-Friends or Foes? Front Endocrinol. 2018;9:155. | eng |
| dcterms.references | Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother Biomedecine Pharmacother. 2021 May;137:111315. | eng |
| dcterms.references | Li X, Chang X, Dang Y, Xue Y, Wang Q, Liu W, et al. Additive interactions between obesity and insulin resistance on hypertension in a Chinese rural population. BMC Public Health. 2023 Dec 15;23(1):2519. | eng |
| dcterms.references | Whaley-Connell A, Sowers JR. Insulin Resistance in Kidney Disease: Is There a Distinct Role Separate from That of Diabetes or Obesity? Cardiorenal Med. 2017 Dec;8(1):41–9. | eng |
| dcterms.references | Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol JASN. 2005 July;16(7): 2134–40. | eng |
| dcterms.references | García-Carro C, Vergara A, Bermejo S, Azancot MA, Sellarés J, Soler MJ. A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management. Front Med. 2021;8:655871. | eng |
| dcterms.references | Liu S, Sun H, Liu J, Wang G. Accessing the relationship between six surrogate insulin resistance indexes and the incidence of rapid kidney function decline and the progression to chronic kidney disease among middleaged and older adults in China: Results from the China health and retirement longitudinal study. Diabetes Res Clin Pract. 2024 June;212:111705. | eng |
| dcterms.references | Arabi T, Shafqat A, Sabbah BN, Ashraf N, Shah H, Abdulkader H, et al. Obesity-related kidney disease: Beyond hypertension and insulin-resistance. Front Endocrinol. 2022;13:1095211. | eng |
| dcterms.references | Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997 Oct 9;389(6651):610–4. | eng |
| dcterms.references | Moriconi D, Antonioli L, Masi S, Bellini R, Pellegrini C, Rebelos E, et al. Glomerular hyperfiltration in morbid obesity: Role of the inflammasome signalling. Nephrol Carlton Vic. 2022 Aug;27(8):673–80. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion |